Cytokeratin13抗体;Cytokeratin13 Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Cytokeratin 13 expression in A431 cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human tonsil, using Cytokeratin 13 Antibody.    

  
  

Cytokeratin 13 (CK13) is a member of the cytokeratin family, a group of structural proteins that form intermediate filaments in epithelial cells. As a type I acidic cytokeratin (K13), it pairs with type II basic cytokeratin 4 (K4) to establish the cytoskeletal framework in non-keratinized stratified epithelia, such as those lining the oral mucosa, esophagus, cervix, and vaginal tract. CK13 is predominantly expressed in differentiated, post-mitotic epithelial cells, playing a critical role in maintaining tissue integrity and mechanical resilience. Its expression is often inversely correlated with cell proliferation, making it a marker for epithelial maturation.

Antibodies targeting CK13 are widely used in immunohistochemistry (IHC) and immunofluorescence (IF) to study epithelial differentiation, tissue-specific pathologies, and neoplasms. In cancer research, reduced CK13 expression is associated with malignant progression in squamous cell carcinomas (e.g., head and neck cancers), where loss of differentiation markers signifies tumor dedifferentiation and aggressive behavior. CK13 antibodies also aid in diagnosing benign conditions, such as oral lichen planus or leukoplakia, by highlighting abnormal epithelial differentiation patterns.

Commercially available CK13 antibodies (monoclonal or polyclonal) are typically validated for cross-reactivity and specificity across human and rodent tissues. Researchers must optimize protocols (e.g., antigen retrieval methods) for accurate detection, given potential variations in fixation and embedding techniques. As a ~54 kDa protein, CK13 is detectable via Western blot, though its primary utility remains in tissue-based applications.